Natera (NASDAQ: NTRA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Natera to related companies based on the strength of its risk, valuation, dividends, earnings, profitability, analyst recommendations and institutional ownership.
This is a breakdown of current ratings and recommmendations for Natera and its peers, as provided by MarketBeat.
||Strong Buy Ratings
Natera presently has a consensus target price of $14.75, indicating a potential upside of 38.63%. As a group, “Medical laboratories” companies have a potential upside of 15.62%. Given Natera’s stronger consensus rating and higher probable upside, equities analysts clearly believe Natera is more favorable than its peers.
This table compares Natera and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility and Risk
Natera has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Natera’s peers have a beta of 1.23, meaning that their average stock price is 23% more volatile than the S&P 500.
Insider & Institutional Ownership
67.1% of Natera shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 13.2% of Natera shares are owned by insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Natera and its peers revenue, earnings per share (EPS) and valuation.
Natera’s peers have higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Natera Company Profile
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.